Overview

Esmolol Effects on Heart and Inflammation in Septic Shock

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Beta adrenergic system, over-activated in septic shock patients, is a key modulator of the inflammatory response. Experimental works demonstrated that Esmolol, an highly selective beta-1 blocker, reduces heart rate and regulates the inflammatory response. A recent mono centric, double blind, randomized clinical work in septic shock patients has shown that Esmolol administration is safe and reduces effectively heart rate. However there are only sparse data on 1) regional and micro-circulation, 2) inflammation modulation in human resuscitated septic shock patients treated by esmolol.
Phase:
Phase 2
Details
Lead Sponsor:
Central Hospital, Nancy, France
Collaborator:
Baxter Healthcare Corporation
Treatments:
Esmolol